
http://eprints.gla.ac.uk/8048/

Deposited on: 5 November 2009
Does the Prevention of Complications Explain the Survival Benefit of Organized Inpatient (Stroke Unit) Care?: Further Analysis of a Systematic Review
Lindsay Govan, Peter Langhorne, Christopher J. Weir and for the Stroke Unit Trialists Collaboration

*Stroke* 2007;38;2536-2540; originally published online Aug 9, 2007;
DOI: 10.1161/STROKEAHA.106.478842

Stroke is published by the American Heart Association. 7272 Greenville Avenue, Dallas, TX 72514
Copyright © 2007 American Heart Association. All rights reserved. Print ISSN: 0039-2499. Online ISSN: 1524-4628

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://stroke.ahajournals.org/cgi/content/full/38/9/2536
Does the Prevention of Complications Explain the Survival Benefit of Organized Inpatient (Stroke Unit) Care?  
Further Analysis of a Systematic Review

Lindsay Govan, BSc, Hons; Peter Langhorne, PhD; Christopher J. Weir, PhD;  
for the Stroke Unit Trialists Collaboration

Background and Purpose—Systematic reviews have shown that organized inpatient (stroke unit) care reduces the risk of death after stroke. However, it is unclear how this is achieved. We tested whether stroke unit care could reduce deaths by preventing complications.

Methods—We updated a collaborative systematic review of 31 controlled clinical trials (6936 participants) to include reported interventions and complications during early hospital care plus the certified cause of death during follow up. Each secondary analysis used data from between 7 and 17 studies (1652 to 3327 participants). Complications were grouped as physiological, neurological, cardiovascular, complications of immobility, and others. Bayesian hierarchical models were used to estimate odds ratios for features occurring in stroke units versus conventional care.

Results—Based on the data of 17 trials (3327 participants), organized (stroke unit) care reduced case fatality during scheduled follow up (OR: 0.75; 95% credible intervals: 0.59 to 0.92), in particular deaths certified as attributable to complications of immobility (0.59; 0.41 to 0.86). Stroke unit care was associated with statistically significant increases in the reported use of oxygen (2.39; 1.39 to 4.66), measures to prevent aspiration (2.42; 1.36 to 4.36), and paracetamol (2.80; 1.14 to 4.83) plus a nonsignificant reduction in the use of urinary catheterization. Stroke units were associated with statistically significant reductions in stroke progression/recurrence (0.66; 0.46 to 0.95) and in some complications of immobility: chest infections (0.60; 0.42 to 0.87), other infections (0.56; 0.40 to 0.84), and pressure sores (0.44; 0.22 to 0.85). There were no significant differences in cardiovascular, physiological, or other complications.

Conclusions—Organized inpatient (stroke unit) care appears to reduce the risk of death after stroke through the prevention and treatment of complications, in particular infections. (Stroke. 2007;38:2536-2540.)

Key Words: complications ■ meta-analysis ■ stroke outcome ■ stroke units

It has been known for many years that organized inpatient (stroke unit) care reduces the risk of death after stroke, but it is not clear how this benefit is achieved. The Stroke Unit Trialists Collaboration carried out an analysis 10 years ago that suggested that stroke units may reduce deaths through preventing complications. However, this analysis had limited statistical power and its conclusions were speculative.

In the most recent update of the stroke unit systematic review, data were available from a larger number of controlled clinical trials. This allowed us to revisit the question “does the prevention of complications explain the survival benefit of stroke unit care?” If this is the case, then we would expect the following observations to be associated with stroke unit care: (1) the more frequent use of interventions designed to prevent complications; (2) a smaller number of recorded serious complications; and (3) fewer deaths attributed to complications.

We report a further analysis of the stroke unit review that addresses these questions.

Methods

Methods of the Review

This is a further analysis of a collaborative systematic review carried out by the Stroke Unit Trialists Collaboration. In summary, this involved rigorous searching for clinical trials of organized inpatient (stroke unit) care, the formation of a collaborative group comprising the primary trialists, the collation of extensive descriptive information and outcome data, and the analysis of these data using rigorous meta-analysis methods. For the current analysis, we used a very broad definition of stroke unit care and included any trial that compared organized (stroke unit) care (defined as a multidisciplinary team specializing in stroke care) versus the contemporary conventional care such as a general medical ward or less organized form of stroke care. Stroke unit care could include services based in a discrete ward or provided by a mobile stroke team. In addition to the existing data, we sought information on the following outcomes: (1)
specific interventions directed at reducing complications; (2) complications recorded during early hospital care (first 4 weeks); and (3) certified cause of death during follow up. The exact criteria used were those defined in the individual trials.

The majority of trials recorded cause of death at the end of scheduled follow up with the exception of three trials that recorded at discharge.4–6 three trials that recorded at an earlier fixed time point,7–9 and one trial with incomplete data.10 The median time for recorded cause of death was 6 months with an interquartile range of 3 to 12 months.

Complications were classified into four categories to reflect previous epidemiological work linking complications to cause of death11: (1) neurological (cerebral edema, stroke recurrence, stroke progression, seizures, anxiety, depression); (2) cardiovascular complications (myocardial infarction, arrhythmia, congestive cardiac failure); (3) complications of immobility (chest infection, urinary tract infection, other infections, dehydration, venous thromboembolism, falls, pressure sores, pain); and (4) other complications (e.g., cancer, gastrointestinal hemorrhage, suicide).

In addition, we also recorded common “physiological complications,” which were defined as physiological abnormalities that did not fulfill a conventional medical diagnosis. These included hypertension, hyperglycemia, hypoxia, hypotension, and pyrexia. The specific definitions of these complications were reported within the original trials.

The specific interventions directed at reducing complications included antibiotics, measures to prevent aspiration (systematic assessment of swallowing and modification of dietary intake), fluids, insulin, oxygen, paracetamol, tube feeding, and urinary catheterization.

### Statistical Methods

Data were analyzed using a hierarchical Bayesian approach12 in WinBUGS. A direct random effects model was used to calculate ORs and 95% credible intervals (CrI). The direct model does not require the assumption of normality for the raw data because it allows us to directly model the numbers of patients with particular outcomes. The assumption of normality can often fail when there are small numbers of trials or events within trials therefore this is a great advantage in this analysis. The random effects model allows the calculated study-specific effects (log ORs) to be different from each other but assumes they are from a common distribution, in this case the Normal distribution. In other words, it assumes that all trials are similar but not identical.13 The fitted model was checked for adequacy and found to be acceptable. Sensitivity for the range of assumptions required for this model was also checked.

In addition, absolute risk differences were calculated using the DerSimonian and Laird14 approach using Revman software.15 This is a variation on the inverse-variance method that weights trials according to the extent of variation among treatment effects across trials.14 The DerSimonian and Laird approach also adjusts the standard errors of the trial-specific effects to incorporate a measure of the extent of heterogeneity among treatment effects observed in different trials.14

### Results

The updated systematic review contains 31 controlled clinical trials (6936 participants).1 A subset of these trials was able to provide much more detailed data for further analyses as outlined subsequently. Further details of the included trials are summarized in a related review.3

### Interventions to Prevent Complications

Data were available for seven trials (1652 participants).8,16–21 The results of this analysis are shown in Figure 1, which indicated that the use of the following interventions were significantly associated with stroke unit care: measures to prevent aspiration (OR: 2.4; 95% CrI: 1.4 to 4.4); oxygen therapy (2.4; 1.4 to 4.7); paracetamol (2.8; 1.1 to 4.8); and possibly a reduced use of urinary catheter (0.6; 0.3 to 1.1).

### Complications During Acute Hospital Stay

Complications data were available for eight trials (1824 participants).6,8,18–23 The main findings are summarized in Table 1. Statistically significant reductions in complications were seen in stroke units for the examples of stroke progression or recurrence, chest infection, other infections, falls, and pressure sores. None of the recorded physiological complications were significantly reduced (Figure 2).

### Certified Cause of Death

Information on certified cause of death was available for 17 trials (3327 participants).4–10,18,19,21,23–29 Within this group of trials, organized (stroke unit) care resulted in reduced all-cause case fatality (OR: 0.75; 95% CrI: 0.59 to 0.92). The results for certified cause of death are summarized in Table 2.

<table>
<thead>
<tr>
<th>Intervention</th>
<th>Number of events: stroke unit (%)</th>
<th>Number of events: control (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antibiotics</td>
<td>109 (36.6)</td>
<td>75 (24.5)</td>
</tr>
<tr>
<td>Aspiration prevention</td>
<td>44 (28.9)</td>
<td>22 (14.5)</td>
</tr>
<tr>
<td>Fluids</td>
<td>473 (76.5)</td>
<td>319 (48.4)</td>
</tr>
<tr>
<td>Insulin</td>
<td>46 (8.6)</td>
<td>34 (6.3)</td>
</tr>
<tr>
<td>Oxygen</td>
<td>185 (52.3)</td>
<td>120 (33.9)</td>
</tr>
<tr>
<td>Paracetamol</td>
<td>212 (37.9)</td>
<td>106 (18.7)</td>
</tr>
<tr>
<td>Tube feeding</td>
<td>58 (26.7)</td>
<td>27 (12.4)</td>
</tr>
<tr>
<td>Urinary Catheter</td>
<td>72 (21.1)</td>
<td>99 (29.3)</td>
</tr>
</tbody>
</table>

Figure 1. Frequency of intervention use in stroke units and conventional care. Results in plot are presented as (median) ORs of use of interventions in stroke units versus conventional care. ORs are represented by the shaded diamond with corresponding 95% CrIs represented by the line. Results are plotted on the log scale.
and indicated that significant reductions in deaths were observed for complications of immobility (0.59; 0.41 to 0.86) but not for any other categories. When these are analyzed as absolute risk difference, we see that there is a reduction in deaths attributed to complications of immobility of approximately one to 2 deaths per 100 patients with stroke. We carried out sensitivity analysis because Bayesian analyses can be sensitive to the choice of priors and initial values. The conclusions were unaffected by choice of prior distribution and initial values.

### Discussion

It has been recognized over the last decade that patients who are managed in an organized inpatient (stroke unit) setting are more likely to survive, return home, and regain independence than those managed in conventional care settings. However, there has been considerable uncertainty as to why this benefit may occur and how stroke unit care could influence outcomes. In a previous analysis from the Stroke Unit Trialists Collaboration, it was suggested that some of the survival benefit of stroke unit care may be explained by a reduction in complications. However, there was limited statistical power to carry out this analysis. In the current update, we had access to considerably larger amounts of data, which indicated that stroke unit care appeared to reduce complications of immobility (in particular, infections), although there were also reductions in stroke recurrence or progression. The current analysis suggests that some of these reductions could be

<table>
<thead>
<tr>
<th>Complication</th>
<th>Number of events: Stroke unit (%)</th>
<th>Number of events: Control (%)</th>
<th>OR (median)</th>
<th>95% CrI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neurological</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anxiety or depression</td>
<td>112 (16.7)</td>
<td>132 (19.7)</td>
<td>0.74</td>
<td>(0.27–1.97)</td>
</tr>
<tr>
<td>Seizures</td>
<td>15 (2.7)</td>
<td>17 (3.1)</td>
<td>0.86</td>
<td>(0.37–1.95)</td>
</tr>
<tr>
<td>Stroke progression or recurrence*</td>
<td>85 (9.4)</td>
<td>121 (13.5)</td>
<td>0.66</td>
<td>(0.46–0.95)</td>
</tr>
<tr>
<td>Cardiovascular†</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chest infection</td>
<td>87 (12.0)</td>
<td>134 (18.6)</td>
<td>0.60</td>
<td>(0.42–0.87)</td>
</tr>
<tr>
<td>Other infections‡</td>
<td>122 (13.5)</td>
<td>201 (21.9)</td>
<td>0.56</td>
<td>(0.40–0.84)</td>
</tr>
<tr>
<td>Dehydration</td>
<td>21 (5.1)</td>
<td>43 (10.1)</td>
<td>0.81</td>
<td>(0.31–2.53)</td>
</tr>
<tr>
<td>Venous thromboembolism§</td>
<td>30 (4.4)</td>
<td>35 (5.0)</td>
<td>0.85</td>
<td>(0.49–1.49)</td>
</tr>
<tr>
<td>Falls</td>
<td>28 (18.4)</td>
<td>43 (28.3)</td>
<td>0.57</td>
<td>(0.33–0.97)</td>
</tr>
<tr>
<td>Pressure sores</td>
<td>21 (4.7)</td>
<td>43 (8.6)</td>
<td>0.44</td>
<td>(0.22–0.85)</td>
</tr>
<tr>
<td>Pain</td>
<td>70 (12.1)</td>
<td>71 (12.3)</td>
<td>0.73</td>
<td>(0.14–2.60)</td>
</tr>
<tr>
<td>Other complications</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>22 (2.9)</td>
<td>24 (3.1)</td>
<td>0.95</td>
<td>(0.46–2.10)</td>
</tr>
</tbody>
</table>

Results are presented as ORs with 95% CrI of complications in stroke units versus conventional care.

*Stroke progression and early recurrence were often not distinguished in the original trials.
†Individual cardiovascular complications (eg, ischemic heart disease, arrhythmia) were usually grouped together.
‡Predominantly urinary tract infection.
§Includes deep vein thrombosis and pulmonary embolism.
would also be less likely to experience complications associated with the last stages of life. Our analysis cannot conclusively discriminate between these competing possibilities.

Despite these remaining uncertainties, we conclude that our findings emphasize the potential importance of complications as a treatable factor in stroke outcome. Future research should explore the best ways of preventing and managing specific complications, particularly those that seem to carry a high risk of causing harm.

Acknowledgments

L.G. updated the systematic review and drafted the updated report; P.L. initiated and coordinated the review project and, with C.J.W., was principal grant holder and revised the updated report.

The SUTC provided the following contributions: Martin Dennis, Graeme Hankey, and Brian Williams contributed to the writing committee, which was responsible for the redrafting of the report.

The following collaborators provided original data, advice and comment, and assisted with the redrafting of the report: K. Asplund (Umeå, Sweden); P. Berman (Nottingham, UK); C. Blomstrand (Göteborg, Sweden); M. Britton (Stockholm, Sweden); N. L. Cabral (Joinville, Brazil); A. Cavallini (Pavia, Italy); P. Dey (Manchester, UK); E. Hamrin (Uppsala, Sweden); G. Hankey (Perth, Australia); B. Indredavik (Trondheim, Norway); L. Kalra (Orpington, UK); M. Kaste (Helsinki, Finland); S. O. Laursen (Svendborg); R. H. Ma (Beijing, China); N. Patel (Cape Town, South Africa); H. Rodgers (Newcastle, UK); M. O. Ronning (Akershus, Norway); J. Sivenius (Kuopio, Finland); G. Slater (Groningen, The Netherlands); A. Svensson (Göteborg, Sweden); K. Vemmos (Athens, Greece); S. Wood-Dauphinee (Montreal, Canada); and H. Yagura (Osaka, Japan).

Source of Funding

L.G. is supported by a Chest Heart and Stroke Scotland research studentship.

Disclosures

None.

References


